External validation of a deep learning-based algorithm for detection of tall cells in papillary thyroid carcinoma: A multicenter study.

Artificial intelligence Deep learning Digital pathology Papillary thyroid carcinoma

Journal

Journal of pathology informatics
ISSN: 2229-5089
Titre abrégé: J Pathol Inform
Pays: United States
ID NLM: 101528849

Informations de publication

Date de publication:
Dec 2024
Historique:
received: 25 09 2023
revised: 03 01 2024
accepted: 29 01 2024
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 1 3 2024
Statut: epublish

Résumé

The tall cell subtype (TC-PTC) is an aggressive subtype of papillary thyroid carcinoma (PTC). The TC-PTC is defined as a PTC comprising at least 30% epithelial cells that are three times as tall as they are wide. In practice, this definition is difficult to adhere to, resulting in high inter-observer variability. In this multicenter study, we validated a previously trained deep learning (DL)-based algorithm for detection of tall cells on 160 externally collected hematoxylin and eosin (HE)-stained PTC whole-slide images. In a test set of 360 manual annotations of regions of interest from 18 separate tissue sections in the external dataset, the DL-based algorithm detected TCs with a sensitivity of 90.6% and a specificity of 88.5%. The DL algorithm detected non-TC areas with a sensitivity of 81.6% and a specificity of 92.9%. In the validation datasets, 20% and 30% TC thresholds correlated with a significantly shorter relapse-free survival. In conclusion, the DL algorithm detected TCs in unseen, external scanned HE tissue slides with high sensitivity and specificity without any retraining.

Identifiants

pubmed: 38425542
doi: 10.1016/j.jpi.2024.100366
pii: S2153-3539(24)00005-1
pmc: PMC10901856
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100366

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

Johan Lundin is a co-founder and board member, and Mikael Lundin is a co-founder and director of concept design at Aiforia Technologies Oy, Helsinki Finland.

Auteurs

Sebastian Stenman (S)

Institute for Molecular Medicine Finland - FIMM, University of Helsinki, Tukholmankatu 8, 00290 Helsinki, Finland.
HUSLAB, Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 3C, 000290 HUS Helsinki, Finland.
Department of Surgery, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland.

Sylvain Bétrisey (S)

Institute of Tissue Medicine and Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland.

Paula Vainio (P)

Department of Pathology, University of Turku, Turku University Hospital, Kiinamyllykatu 10, 20520 Turku, Finland.

Jutta Huvila (J)

Department of Pathology, University of Turku, Turku University Hospital, Kiinamyllykatu 10, 20520 Turku, Finland.

Mikael Lundin (M)

Institute for Molecular Medicine Finland - FIMM, University of Helsinki, Tukholmankatu 8, 00290 Helsinki, Finland.

Nina Linder (N)

Institute for Molecular Medicine Finland - FIMM, University of Helsinki, Tukholmankatu 8, 00290 Helsinki, Finland.
Institute of Pathology, Klinikum Stuttgart, Kriegsbergstraße 60, 70174 Stuttgart, Germany.

Anja Schmitt (A)

Institute of Tissue Medicine and Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland.

Aurel Perren (A)

Institute of Tissue Medicine and Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland.

Matthias S Dettmer (MS)

Institute of Tissue Medicine and Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland.
The Global Health & Migration Department of Women's and Children's Health, Uppsala University, 75185 Uppsala, Sweden.

Caj Haglund (C)

Department of Surgery, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland.
Research Programs Unit, Translational Cancer Medicine, University of Helsinki, Haartmaninkatu 4, 00290 Helsinki, Finland.

Johanna Arola (J)

HUSLAB, Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 3C, 000290 HUS Helsinki, Finland.

Johan Lundin (J)

Institute for Molecular Medicine Finland - FIMM, University of Helsinki, Tukholmankatu 8, 00290 Helsinki, Finland.
Department of Global Public Health, Karolinska Institutet, Norrbackagatan 4, 17176 Stockholm, Sweden.
iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.

Classifications MeSH